Expert Analysis: Longboard Pharma Stock Target Raised and Buy Rating Reiterated on Study Results
Monday, 10 June 2024, 17:55
Longboard Pharma Stock Target Raised and Buy Rating Reiterated on Study Results
Longboard Pharma has seen its stock target raised with a reiterated Buy rating based on the latest study results.
Investors are advised to closely monitor Longboard Pharma given the positive outlook and reaffirmed confidence in its performance.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.